Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

RBSH Rebus Holdings Inc (CE)

0.00 (0.00%)
Last Updated: 20:00:00
Delayed by 15 minutes


Draw Mode:

Volume 0.00
Bid Price
Ask Price
News -
Day High


52 Week Range


Day Low
Company Name Stock Ticker Symbol Market Type
Rebus Holdings Inc (CE) RBSH OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 0.000001 20:00:00
Open Price Low Price High Price Close Price Prev Close
Trades Volume Avg Volume 52 Week Range
0 0.00 - 0.000001 - 0.02255
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.000001 USD

Rebus Holdings Inc (CE) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
0 32.13M - 0 -1.02M -0.03 0.00
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Rebus (CE) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No RBSH Message Board. Create One! See More Posts on RBSH Message Board See More Message Board Posts

Historical RBSH Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.
1 Month0.0000010.00010.0000010.0000013,7690.000.00%
3 Months0.00010.00010.0000010.0000995269,679-0.0001-99.00%
6 Months0.00650.00880.0000010.0021868254,606-0.0065-99.98%
1 Year0.00760.022550.0000010.0080075138,769-0.0076-99.99%
3 Years0.09990.120.0000010.0226551277,389-0.0999-100.00%
5 Years0.09990.120.0000010.0226551277,389-0.0999-100.00%

Rebus (CE) Description

Inspyr Therapeutics develops curative cancer therapies that are core to the principles of finding the best way to cure or extend human life. Its innovative approach to drug delivery is expected to maximize anti-tumor activity while minimizing side effects. Inspyr's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of the company's drug candidates within a tumor. Inspyr's lead drug candidate, mipsagargin, is activated by the enzyme PSMA, which is found at high levels in the blood vessels of liver and glioblastoma cancers and in the blood vessels of almost all other solid tumors. Mipsagargin is expected to have potential efficacy in a wide variety of tumor types.

Your Recent History

Delayed Upgrade Clock